Collaborative and Service Projects
Our collaborative projects help to development individual TR&D projects, while service projects provide mature technology and materials to investigators. Collaborative projects (CPs) drive our TR&D research programs. They are a diverse set of collaborations spread across the US, including projects on both coasts and in Ohio and Indiana. The investigators span the field of immunoengineering – from basic science aspects of engineering to translational immunotherapy. Many of them interact with multiple TR&Ds. Our service projects are linked to a specific TR&D and our partners include both academic and biotech companies, such as NexImmune, Sanofi, and GSK.
Use of large-scale genomic analyses and functional dissection to determine what drives oncogenesis to develop improved diagnostic and therapeutic modalities for human cancers.
Safe and efficient siRNA delivery to macrophages to enable new treatments for human diseases.
Defining neo-antigens using established software algorithms.
Identifying the antigen-specific responses to either shared AML tumor antigens or neoantigens.
Replace viral gene therapy biotechnology tools with non-viral gene therapy biotechnology tools.
Applying our large library of nanoparticles to the challenge of ex vivo stem cell engineering.
Delivery of mRNA to reprogram “cold” tumor immune microenvironment.
Separating individual cells based on their molecular secretion profiles.
Suppression of rAAV immunity to improve the efficacy of rAAV-microdystrophin gene therapy and enable repeat dosing.
Reducing the burden of anti-drug antibodies with IL-2-based immunocytokine.
Synthesize and validate artificial antigen presenting cells (aAPC) in pre-clinical AML models.
Metabolic programming of aAPC NP- and MP-stimulated T cells.
Develop a biomaterials-based modular ex vivo organoid platform with the ability to generate high affinity, antigen specific antibodies ex vivo.
Elucidate the mechanisms underlying age-associated changes in T cells.
Develop non-lipid nanoparticles for mRNA delivery, especially to immune cells.
Creation of non-viral agents for gene transfer to the retina.
Use of CRISPR/Cas9 genome editors for HIV treatment.
Elucidating the role of integrins in modulating T cell signaling.
Understand signals in the lymph node microenvironment to enable potent, myelin-specific immunotherapies that avoid immunosuppression.
Designing NPs that engage and expand both CD4+ and CD8+ Tregs in vivo as a novel treatment for the autoimmune disease systemic lupus erythematosus.
